Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Aminoglycoside antibacterial (inhaled liposomal)

Arikayce (amikacin liposome inhalation suspension)

An approved treatment for Nontuberculous Mycobacterial Lung Disease.

FDA Approved (2018)by Insmed Incorporated
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2018

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Amikacin liposome inhalation suspension wherever you encounter it, plus the key facts at a glance.

Generic name
Amikacin liposome inhalation suspension
Brand name
Arikayce
Development codes
ALIS, LAI
Drug class
Aminoglycoside antibacterial (inhaled liposomal)
Manufacturer
Insmed Incorporated
How it's taken
Inhaled once a day through the Lamira nebulizer, added to other MAC antibiotics

A once-daily inhaled antibiotic for adults with Mycobacterium avium complex (MAC) lung disease who have limited or no other treatment options.

  • It is for people whose sputum still grows MAC after at least 6 months of a multidrug antibiotic regimen[1]. It is breathed in through the Lamira nebulizer and added to the other antibiotics.
  • The FDA granted accelerated approval on September 28, 2018, based on sputum culture results, and the label says clinical benefit has not yet been established[2].
  • Arikayce carries a boxed warning for breathing-related side effects.
  • Insmed has asked the FDA for full approval and a wider label, with a decision due January 28, 2027[4].
Email me the day the FDA decides on Arikayce

The decision is expected by January 28, 2027. One email when it is public, with what it means in plain language, plus new trials for Nontuberculous Mycobacterial Lung Disease and FDA news. Unsubscribe anytime.

You'll get, for Nontuberculous Mycobacterial Lung Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Amikacin liposome inhalation suspension fits

Arikayce (amikacin liposome inhalation suspension) is approved for adults whose MAC lung disease persists after at least 6 months of multidrug antibiotics and who have few other options[1].

  • Under the 2020 ATS/ERS/ESCMID/IDSA guideline, standard care for MAC lung disease is 3 antibiotics: azithromycin or clarithromycin, rifampin or rifabutin, and ethambutol[10].
  • The guideline suggests continuing them for at least 12 months after sputum cultures turn negative[10].
  • The guideline suggests adding intravenous amikacin or streptomycin at the start for cavitary, advanced or macrolide-resistant disease[10].
  • For MAC still positive after 6 months of that regimen, the 2020 guideline recommends adding Arikayce[10].
  • Arikayce's label trial compared it with the background regimen alone, and no trial on the label compares it with intravenous amikacin[1].
  • The FDA's decision on full approval and on use earlier in MAC lung disease, including newly diagnosed infection, is due January 28, 2027[4][6].
  • A question to bring to a lung or infectious disease specialist is how sputum results, hearing checks and a daily nebulizer routine would fit into the current treatment plan.

How Amikacin liposome inhalation suspension works

Insmed says the MAC infection resides inside the lung's cleanup cells, called macrophages[4]. Amikacin is an older antibiotic that kills bacteria by binding the 30S part of the ribosome, the machinery a germ uses to build proteins[1]. Given into a vein, amikacin is known for damaging hearing, balance and the kidneys, according to Insmed[4].

Arikayce packs amikacin inside liposomes, tiny bubbles made of cholesterol and a fat called DPPC, and is breathed in as a mist[1]. Insmed says lung macrophages take up the liposomes, which puts the drug where the infection is while limiting how much reaches the rest of the body[4]. On the label, blood levels after 3 months of daily use averaged a peak of 2.8mcg/mL, against about 76mcg/mL for the standard intravenous dose in healthy adults[1].

Amikacin levels in sputum vary widely from person to person, and about 7.42% of the dose was found unchanged in the urine on average[1]. Some MAC strains became resistant during treatment. In the main trial, 10.3% of people on Arikayce grew MAC with an amikacin MIC above 64mcg/mL, against 3.6% on the other antibiotics alone[1].

Side effects and safety

What patients report
Boxed warning
Risk of increased respiratory adverse reactions. Arikayce has been linked to hypersensitivity pneumonitis, coughing up blood (hemoptysis), airway tightening (bronchospasm) and flares of the underlying lung disease, which led to hospital stays in some cases.
Label warnings
  • Hypersensitivity pneumonitis. Lung inflammation in 3.1% on Arikayce plus other antibiotics against 0% on other antibiotics alone. Most people who had it stopped Arikayce and were treated with steroids.
  • Coughing up blood. Hemoptysis in 18.4% against 13.4%. The label asks patients to report coughing up blood, especially in the first month.
  • Airway tightening. Bronchospasm, including wheezing and shortness of breath, in 28.7% against 10.7%. Using an inhaled reliever first may be considered for people with asthma, COPD or reactive airways.
  • Flares of underlying lung disease. COPD or bronchiectasis flares in 15.2% against 9.8%.
  • Serious allergic reactions. Anaphylaxis and other serious reactions have been reported. Arikayce is not used in anyone with a known allergy to any aminoglycoside.
  • Hearing and balance damage. Ototoxicity in 17% against 9.8%, mostly ringing in the ears and dizziness. Ringing may be an early sign. Certain mitochondrial MT-RNR1 gene changes raise the risk of permanent hearing loss.
  • Kidney damage. Seen in the trials, though not more often than on other antibiotics alone. Kidney function may be watched more closely in people with kidney problems and in older adults.
  • Muscle weakness. Aminoglycosides can worsen weakness in neuromuscular conditions such as myasthenia gravis. People with these conditions were not enrolled in the trials.
  • Harm to an unborn baby. Aminoglycosides may cause total, permanent deafness in a baby exposed during pregnancy.
  • Other medicines. The label says to avoid other medicines that can harm nerves, kidneys or hearing, and the diuretics ethacrynic acid, furosemide, urea and intravenous mannitol.
Most common in trials
Hoarse or lost voice (48% against 2%)Cough (40% against 17%)Bronchospasm (29% against 11%)Coughing up blood (18% against 13%)Muscle and joint pain (18% against 9%)Throat irritation (18% against 2%)Hearing or balance problems (17% against 10%)Fatigue (16% against 10%)Lung disease flares (15% against 10%)Diarrhea (13% against 5%)Nausea (12% against 4%)Headache (10% against 5%)
What gets monitored
  • Any past allergic reaction to an aminoglycoside, checked before starting
  • Breathing, wheezing and coughing up blood, especially in the first month
  • Hearing, ringing in the ears and balance, more closely with known hearing or balance problems
  • Kidney function in people with kidney problems and in older adults
  • Muscle weakness in people with neuromuscular conditions such as myasthenia gravis
  • Sputum cultures, the measure the accelerated approval was based on
Report a suspected reaction to Insmed at 1-844-4-INSMED, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

Arikayce carries a boxed warning for a higher risk of breathing-related side effects, some of which led to hospital stays. They are hypersensitivity pneumonitis (lung inflammation), coughing up blood (hemoptysis), airway tightening (bronchospasm) and flares of the underlying lung disease[1]. In the main trial, bronchospasm affected 28.7% of people on Arikayce plus their other antibiotics against 10.7% on the other antibiotics alone.

Hemoptysis affected 18.4% against 13.4%, lung disease flares 15.2% against 9.8%, and hypersensitivity pneumonitis 3.1% against 0%[1]. The most common side effect was a hoarse or lost voice (dysphonia), in 48% against 2%. Cough affected 40% against 17%, and throat irritation 18% against 2%[1]. Hearing and balance problems (ototoxicity) affected 17% against 9.8%, driven mostly by ringing in the ears (8.1% against 0.9%) and dizziness (6.3% against 2.7%)[1].

People with certain changes in the mitochondrial MT-RNR1 gene, particularly m.1555A>G, have had hearing damage from aminoglycosides even at normal blood levels[1]. Kidney damage occurred in the trials, though not more often than on the other antibiotics alone. The label also warns that aminoglycosides can worsen muscle weakness in conditions such as myasthenia gravis[1].

Serious allergic reactions, including anaphylaxis, have been reported. Aminoglycosides taken during pregnancy may cause total, permanent deafness in the baby[1]. In the main trial, 34.5% stopped Arikayce early, 18.8% because of side effects, against 10.7% stopping their antibiotics in the comparison group[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Amikacin liposome inhalation suspension

Arikayce is breathed in once a day. The dose is the contents of 1 vial, 590mg of amikacin in 8.4mL, given only with the Lamira Nebulizer System[1]. The vial should be at room temperature and is shaken well for at least 10 to 15 seconds before it is poured into the nebulizer handset[1]. People who use an inhaled reliever (bronchodilator) take it first, and pre-treatment may be considered for people with asthma, COPD or reactive airways[1].

A missed dose is taken the next day, without doubling[1]. Arikayce is added to a multidrug MAC regimen, never used alone[1]. Each carton holds 28 vials, a 28-day supply, with 1 Lamira handset and 4 aerosol heads. Vials are kept in the refrigerator at 2°C to 8°C (36°F to 46°F), or at room temperature up to 25°C (77°F) for up to 4 weeks[1]. The Lamira device should not be used with any other medicine.

The label advises against operating heavy machinery or doing other dangerous activities while inhaling, since Arikayce can cause dizziness[1]. No dose change is listed for liver problems; kidney function should be monitored in people with kidney problems[1].

Availability and cost

No generic available

Only available as the brand-name product.

Why it costs what it costs

A 28-vial monthly kit with the Lamira nebulizer, taken every day for as long as a doctor continues it. The label gives no price. Drugs@FDA lists only Insmed's application (NDA 207356) for this product, with no approved generic[3].

Help paying for Arikayce

The maker of Arikayce publishes no copay card, but its support program can check your insurance and explain any help that exists. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. The charity fund for Nontuberculous Mycobacterial Lung Disease was not taking new applications on November 18, 2026. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Arikayce (Amikacin liposome inhalation suspension)
Some details not published
inLighten Patient Support program
  • Insurance and case manager help

    Insmed's inLighten Patient Support program offers educational resources and other support to eligible patients prescribed Insmed medicines, through access and treatment. Insmed's Arikayce page gives the US number 1-833-LIGHT-00 (1-833-544-4800).

    The official page does not say who qualifies. Ask the program. · source

Good to know: Insmed's pages name the inLighten Patient Support program but give no copay card amount, benefit limit, free-drug program or eligibility rules. Arikayce.com, where those terms may be posted, did not load and was not read. Generic Arikayce is not available.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Nontuberculous Mycobacterial Lung Disease

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for Nontuberculous Mycobacterial Lung Disease →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

The 2018 approval rested on CONVERT (Trial 1, NCT02344004), an open-label trial in adults whose MAC lung disease had not cleared after at least 6 months of a multidrug regimen[1][7]. It randomized 336 people 2 to 1 to Arikayce plus their regimen (224) or the regimen alone (112). Their mean age was 64.7, 69.3% were women and 62.5% had bronchiectasis[1].

Culture conversion, 3 negative monthly sputum cultures in a row by month 6, was reached by 29.0% on Arikayce against 8.9% on the regimen alone (p<0.0001)[1]. Conversion that held through 12 months of treatment was reached by 18.3% against 2.7%, and 16.1% against 0% were still converted 3 months after treatment ended[1]. The 6-minute walk test and the St George's Respiratory Questionnaire showed no clinical benefit by month 6[1].

The results were published in 2018 (Griffith et al.)[9]. The FDA required a further randomized, double-blind, placebo-controlled trial to confirm clinical benefit[2]. Insmed says ENCORE (NCT04677569) was the study run to meet that requirement[4]. It enrolled 425 adults with a new MAC lung infection who had not yet had antibiotics for it[8]. They were randomized to Arikayce or an inhaled empty-liposome placebo for 12 months, each with azithromycin 250mg and ethambutol 15mg/kg[5].

Insmed reported on March 23, 2026 that ENCORE met its main goal. The respiratory symptom score improved by 17.77 points on Arikayce against 14.66 on placebo at month 13 (p=0.0299)[5]. Cultures converted by month 6 in 87.8% against 57.0%, and 76.2% against 47.6% stayed converted at month 15. The PROMIS fatigue score did not differ significantly (p=0.2900)[5].

In ENCORE, a hoarse voice affected 58.7% against 8.5%, and 14.6% against 8.5% stopped treatment because of side effects, according to Insmed. No death was considered related to Arikayce or placebo[5]. ENCORE results are not on the FDA label.

Development history

Insmed submitted the application on March 28, 2018[2]. The FDA approved Arikayce on September 28, 2018 under accelerated approval, with priority review and orphan drug designation[2][3]. Arikayce was also approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), and its label begins with the words LIMITED POPULATION[2][1].

Insmed says Arikayce was the first product approved under that pathway[4]. The approval letter required a randomized, double-blind, placebo-controlled trial to assess clinical benefit[2]. Insmed says ENCORE was the study run to meet that requirement[4]. Insmed reported ENCORE's results on March 23, 2026[5]. On September 21, 2026 Insmed announced that the FDA had accepted its supplemental application for full approval, with priority review and a target action date of January 28, 2027[4].

Insmed says the application seeks full approval for the current use and a label expansion to all patients with MAC lung disease[6]. Arikayce is also approved in Europe and Japan, according to Insmed[4]. The current US label was revised in June 2026[1].

Ask anything about Amikacin liposome inhalation suspension
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Nontuberculous Mycobacterial Lung Disease trials

Common questions about Amikacin liposome inhalation suspension

▸What is Amikacin liposome inhalation suspension (Arikayce)?

A once-daily inhaled antibiotic for adults with Mycobacterium avium complex (MAC) lung disease who have limited or no other treatment options. It is for people whose sputum still grows MAC after at least 6 months of a multidrug antibiotic regimen[1]. It is breathed in through the Lamira nebulizer and added to the other antibiotics. The FDA granted accelerated approval on September 28, 2018, based on sputum culture results, and the label says clinical benefit has not yet been established[2]. Arikayce carries a boxed warning for breathing-related side effects. Insmed has asked the FDA for full approval and a wider label, with a decision due January 28, 2027[4].

▸How does Amikacin liposome inhalation suspension work?

Insmed says the MAC infection resides inside the lung's cleanup cells, called macrophages[4]. Amikacin is an older antibiotic that kills bacteria by binding the 30S part of the ribosome, the machinery a germ uses to build proteins[1]. Given into a vein, amikacin is known for damaging hearing, balance and the kidneys, according to Insmed[4]. Arikayce packs amikacin inside liposomes, tiny bubbles made of cholesterol and a fat called DPPC, and is breathed in as a mist[1]. Insmed says lung macrophages take up the liposomes, which puts the drug where the infection is while limiting how much reaches the rest of the body[4]. On the label, blood levels after 3 months of daily use averaged a peak of 2.8mcg/mL, against about 76mcg/mL for the standard intravenous dose in healthy adults[1]. Amikacin levels in sputum vary widely from person to person, and about 7.42% of the dose was found unchanged in the urine on average[1]. Some MAC strains became resistant during treatment. In the main trial, 10.3% of people on Arikayce grew MAC with an amikacin MIC above 64mcg/mL, against 3.6% on the other antibiotics alone[1].

▸What are the side effects of Amikacin liposome inhalation suspension?

Arikayce carries a boxed warning for a higher risk of breathing-related side effects, some of which led to hospital stays. They are hypersensitivity pneumonitis (lung inflammation), coughing up blood (hemoptysis), airway tightening (bronchospasm) and flares of the underlying lung disease[1]. In the main trial, bronchospasm affected 28.7% of people on Arikayce plus their other antibiotics against 10.7% on the other antibiotics alone. Hemoptysis affected 18.4% against 13.4%, lung disease flares 15.2% against 9.8%, and hypersensitivity pneumonitis 3.1% against 0%[1]. The most common side effect was a hoarse or lost voice (dysphonia), in 48% against 2%. Cough affected 40% against 17%, and throat irritation 18% against 2%[1]. Hearing and balance problems (ototoxicity) affected 17% against 9.8%, driven mostly by ringing in the ears (8.1% against 0.9%) and dizziness (6.3% against 2.7%)[1]. People with certain changes in the mitochondrial MT-RNR1 gene, particularly m.1555A>G, have had hearing damage from aminoglycosides even at normal blood levels[1]. Kidney damage occurred in the trials, though not more often than on the other antibiotics alone. The label also warns that aminoglycosides can worsen muscle weakness in conditions such as myasthenia gravis[1]. Serious allergic reactions, including anaphylaxis, have been reported. Aminoglycosides taken during pregnancy may cause total, permanent deafness in the baby[1]. In the main trial, 34.5% stopped Arikayce early, 18.8% because of side effects, against 10.7% stopping their antibiotics in the comparison group[1].

▸How is Amikacin liposome inhalation suspension taken?

Arikayce is breathed in once a day. The dose is the contents of 1 vial, 590mg of amikacin in 8.4mL, given only with the Lamira Nebulizer System[1]. The vial should be at room temperature and is shaken well for at least 10 to 15 seconds before it is poured into the nebulizer handset[1]. People who use an inhaled reliever (bronchodilator) take it first, and pre-treatment may be considered for people with asthma, COPD or reactive airways[1]. A missed dose is taken the next day, without doubling[1]. Arikayce is added to a multidrug MAC regimen, never used alone[1]. Each carton holds 28 vials, a 28-day supply, with 1 Lamira handset and 4 aerosol heads. Vials are kept in the refrigerator at 2°C to 8°C (36°F to 46°F), or at room temperature up to 25°C (77°F) for up to 4 weeks[1]. The Lamira device should not be used with any other medicine. The label advises against operating heavy machinery or doing other dangerous activities while inhaling, since Arikayce can cause dizziness[1]. No dose change is listed for liver problems; kidney function should be monitored in people with kidney problems[1].

▸Is Amikacin liposome inhalation suspension FDA approved?

Yes, Amikacin liposome inhalation suspension (Arikayce) is FDA approved (2018) for the treatment of Nontuberculous Mycobacterial Lung Disease.

▸Who is Arikayce approved for?

Adults with MAC lung disease whose sputum still grows MAC after at least 6 months of a multidrug antibiotic regimen, and who have limited or no other options[1].

How it is used: added to the other MAC antibiotics, never alone.

Not recommended: for MAC lung disease that has not reached that point, which the label calls non-refractory.

Age: safety and effectiveness under 18 have not been established.

Source: Arikayce prescribing information, revised June 2026.

▸Is Arikayce fully approved by the FDA?

Not yet. The FDA granted accelerated approval on September 28, 2018, based on sputum cultures turning negative, and the label says clinical benefit has not yet been established[2].

Pending decision: the FDA accepted Insmed's application for full approval with priority review, and the target date is January 28, 2027[4].

What Insmed is asking for: full approval for the current use and a label expansion to all patients with MAC lung disease[6].

Outcome: the FDA has not announced a decision.

Source: FDA approval letter, September 28, 2018; Insmed releases, September 21 and October 29, 2026.

▸What did the ENCORE trial of Arikayce show?

Insmed reported that ENCORE met its main goal in 425 adults with a new MAC lung infection[5].

Symptoms: the respiratory symptom score improved 17.77 points on Arikayce against 14.66 on placebo at month 13 (p=0.0299).

Cultures: 87.8% against 57.0% converted by month 6, and 76.2% against 47.6% stayed converted at month 15.

Fatigue: no significant difference.

Voice: hoarseness affected 58.7% against 8.5%.

Label status: these results are not on the current FDA label.

Source: Insmed release, March 23, 2026.

▸What does the Arikayce boxed warning mean?

The label warns of a higher risk of breathing-related side effects, some of which led to hospital stays[1].

Airway tightening: 28.7% on Arikayce plus other antibiotics against 10.7% on other antibiotics alone.

Coughing up blood: 18.4% against 13.4%.

Lung disease flares: 15.2% against 9.8%.

Lung inflammation (hypersensitivity pneumonitis): 3.1% against 0%.

What to report: shortness of breath, wheezing, coughing up blood or worsening lung disease, especially in the first month.

Source: Arikayce prescribing information, revised June 2026.

▸Can Arikayce cause hearing loss?

Yes. Hearing and balance problems affected 17% on Arikayce against 9.8% on other antibiotics alone in the main trial[1].

Most common: ringing in the ears (8.1% against 0.9%) and dizziness (6.3% against 2.7%).

Early sign: the label says ringing in the ears may be the first symptom.

Gene risk: certain mitochondrial MT-RNR1 changes, particularly m.1555A>G, have led to hearing damage from aminoglycosides even at normal levels.

Pregnancy: aminoglycosides may cause permanent deafness in a baby exposed in the womb.

Source: Arikayce prescribing information, revised June 2026.

▸Is there a generic version of Arikayce?

No. Drugs@FDA lists only Insmed's application, NDA 207356, for amikacin liposome inhalation suspension, with no approved generic[3].

Device: Arikayce is given only with the Lamira Nebulizer System, which comes in the monthly kit.

Support program: Insmed's inLighten Patient Support program is at 1-833-LIGHT-00 (1-833-544-4800)[11].

Source: openFDA Drugs@FDA record, NDA 207356; Insmed.

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Insmed Incorporated via DailyMed · 2026-08-04. ARIKAYCE- amikacin suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=499ab990-2b21-474f-aaba-d86388965f40
  2. FDA · 2018-09-28. NDA 207356 accelerated approval and LPAD pathway approval, ARIKAYCE (amikacin liposome inhalation suspension) 590mg. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/207356Orig1s000ltr.pdf
  3. FDA via openFDA · 2026-06-25. openFDA Drugs@FDA record for NDA 207356, ARIKAYCE KIT. https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207356%22
  4. Insmed Incorporated via PR Newswire · 2026-09-21. FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027. https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-insmeds-snda-for-arikayce-amikacin-liposome-inhalation-suspension-for-treatment-of-mac-lung-disease-with-pdufa-target-action-date-set-for-january-28-2027-302884017.html
  5. Insmed Incorporated · 2026-03-23. Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease. https://investor.insmed.com/2026-03-23-Insmed-Announces-Positive-Topline-Results-from-Phase-3b-ENCORE-Study-of-ARIKAYCE-R-Amikacin-Liposome-Inhalation-Suspension-in-Patients-with-MAC-Lung-Disease
  6. Insmed Incorporated · 2026-10-29. Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update. https://investor.insmed.com/2026-10-29-Insmed-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Business-Update
  7. ClinicalTrials.gov. Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone. https://clinicaltrials.gov/study/NCT02344004
  8. ClinicalTrials.gov. Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex. https://clinicaltrials.gov/study/NCT04677569
  9. American Journal of Respiratory and Critical Care Medicine · 2018-12-15. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. https://pubmed.ncbi.nlm.nih.gov/30216086/
  10. Clinical Infectious Diseases · 2020-08-14. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. https://pubmed.ncbi.nlm.nih.gov/32628747/
  11. Insmed Incorporated. ARIKAYCE (amikacin liposome inhalation suspension). https://insmed.com/therapies/arikayce/
  12. Insmed Incorporated. Patient Access. https://insmed.com/patients/patient-access/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Arikayce by email

We'll email you when Arikayce's FDA label changes, when the FDA acts on it, and when new trials for Nontuberculous Mycobacterial Lung Disease open. Unsubscribe anytime.

You'll get, for Nontuberculous Mycobacterial Lung Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site